- Recent Funding
- Investors
- ROM InWest
ROM InWest portfolio
ROM InWest has 3 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months.
About this page
Its most recent investment on record is Amplio Pharma's Seed round in October 2026, alongside Amsterdam UMC Ventures, Innovatiefonds Noord-Holland and LEH. By category, its portfolio leans toward Health and bio (2) and Manufacturing and industrial (1).
What ROM InWest invests in
- Health and bio · 2 · 67%
- Manufacturing and industrial · 1 · 33%
- Climate and energy · 1 · 33%
- Commerce and retail · 1 · 33%
How ROM InWest invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Seed | 1 100% | undisclosed |
ROM InWest portfolio companies
AAmplio PharmaSeed · Oct 2026
GGreencoverybacker
HHealthplus.aibacker
| Company | Round with ROM InWest | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Seed | $400K | Oct 1, 2026 Seed |
Climate and energy |
backer | undisclosed | Sep 14, 2026 Seed |
Health and bio |
backer | $6.5M | Sep 3, 2026 Seed |
Most frequent co-investors
AAmsterdam UMC Ventures1 shared round · last Oct 1, 2026
IInnovatiefonds Noord-Holland1 shared round · last Oct 1, 2026
LLEH1 shared round · last Oct 1, 2026
Similar investors
OO'Shaughnessy Ventures3 companies · 1 deal in 12 mo
SSide Stage Ventures3 companies
AAble Partners4 companies · 1 deal in 12 mo
IIzou Partners2 companies · 2 deals in 12 mo
- TThe Ljungstrom Family Office2 companies · 2 deals in 12 mo
GGenoa Ventures5 companies · 4 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 1 round on Recent Funding that name ROM InWest. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists ROM InWest, which is a subset of its real portfolio. API: /api/v1/investors/rom-inwest (get a free API key). More: the most active VC firms and new venture capital funds.